Astrocytes in Oligodendrocyte Lineage Development and White Matter Pathology

Jiasi Li1†, Lei Zhang2†, Yongxin Chu3, Michael Namaka4, Benqiang Deng1, Jiming Kong5* and Xiaoying Bi1**

1 Department of Neurology, Shanghai Changhai Hospital, Shanghai, China, 2 Department of Vascular Surgery, Shanghai Changhai Hospital, Shanghai, China, 3 Department of Vascular Surgery, Affiliated Huai’an Hospital of Xuzhou Medical College, Huai’an, China, 4 Faculty of Health Sciences, College of Pharmacy and Medicine, University of Manitoba, Winnipeg, MB, Canada, 5 Department of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, MB, Canada

*Correspondence: Jiming Kong jiming.kong@umanitoba.ca; Xiaoying Bi bxiaoying2013@163.com
† These authors have contributed equally to this work.

White matter is primarily composed of myelin and myelinated axons. Structural and functional completeness of myelin is critical for the reliable and efficient transmission of information. White matter injury has been associated with the development of many demyelinating diseases. Despite a variety of scientific advances aimed at promoting re-myelination, their benefit has proven at best to be marginal. Research suggests that the failure of the re-myelination process may be the result of an unfavorable microenvironment. Astrocytes, are the most ample and diverse type of glial cells in central nervous system (CNS) which display multiple functions for the cells of the oligodendrocyte lineage. As such, much attention has recently been drawn to astrocyte function in terms of white matter myelin repair. They are different in white matter from those in gray matter in specific regards to development, morphology, location, protein expression and other supportive functions. During the process of demyelination and re-myelination, the functions of astrocytes are dynamic in that they are able to change functions in accordance to different time points, triggers or reactive pathways resulting in vastly different biologic effects. They have pivotal effects on oligodendrocytes and other cell types in the oligodendrocyte lineage by serving as an energy supplier, a participant of immunological and inflammatory functions, a source of trophic factors and iron and a sustainer of homeostasis. Astrocytic impairment has been shown to be directly linked to the development of neuromyelities optica (NMO). In addition, astrocytes have also been implicated in other white matter conditions such as psychiatric disorders and neurodegenerative diseases such as Alzheimer's disease (AD), multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). Inhibiting specifically detrimental signaling pathways in astrocytes while preserving their beneficial functions may be a promising approach for remyelination strategies. As such, the ability to manipulate astrocyte function represents a novel therapeutic approach that can repair the damaged myelin that is known to occur in a variety of white matter-related disorders.

Keywords: astrocyte, white matter, oligodendrocyte, demyelination, neurodegeneration, psychiatric disorders
INTRODUCTION

Human white matter makes up approximately half of the forebrain volume, which is 3–4 times higher than that in rodents (Hamner et al., 2011). White matter in the mammalian central nervous system (CNS) is primarily composed of myelin and myelinated axons. Structural and functional completeness of myelin is critical for the reliable and efficient transmission of information. White matter damage caused by ischemia, hypoxia, inflammation and trauma has been associated with the development of primary or secondary demyelinating diseases. Demyelination of white matter is directly correlated with a vast array of clinical symptoms such as but not limited to sensory disturbances, paralysis, psychiatric disorders and cognitive impairments. Despite the variety of scientific advances that have been developed to promote myelin repair, unfortunately, at best they have only had marginal success. Based on the scientific literature, we do know that cells of the oligodendrocyte lineage are responsible for myelinating CNS axons. Oligodendrocyte precursor cells (OPCs) represent the major source of cells that are required to differentiate into mature oligodendrocytes. Oligodendrocytes are responsible for myelination during embryonic development and after a CNS demyelinating event (Crawford et al., 2014). The inability to induce the required production of OPCs is thought to occur due to the failure of the microenvironment to support their regeneration (Fancy et al., 2014).

In the CNS, astrocytes comprise the most ample and diverse type of glial cells found in both white matter and gray matter. They display many essential and complex functions in adult brain and spinal cord. Specifically they are involved in participation and regulation of synaptogenesis (Clarke and Barres, 2013), support and nourishment of ambient parenchymal cells (Allaman et al., 2011), homeostasis maintenance of water, ions and neurotransmitters (Obara et al., 2008; Papadopoulos and Verkman, 2013), development and maintenance of the vasculature scaffold and blood-brain barrier (BBB), as well as modulation of local blood flow (Attwell et al., 2010). As a result, astrocytes represent a very unique cell type that can directly influence the production and survival of cells of the oligodendrocyte lineage.

Astrocytes respond to multiple forms of CNS insult, such as trauma, ischemia, infection, inflammation, neurodegeneration etc. They become “active” or “reactive” with the changes in their morphology, physiology and gene expression (Sofroniew and Vinters, 2010). Research suggests that reactive astrocytes are considered detrimental to myelin repair or the re-myelination process because of their involvement in producing scar tissue and inhibiting OPC survival, differentiation, migration, and axonal connectivity (Wang et al., 2011). However, in recent years, there is accumulating evidence to suggest that astrocytes can also create a permissive environment for oligodendrocyte lineage expansion and differentiation. They demarcate and separate the injured area to limit the spread of toxic factors (Fitch and Silver, 1997) and provide trophic factor to survive the surrounding cells of lesions (do Carmo Cunha et al., 2007). Removal of reactive astrocytes after CNS injury led to larger lesions, severe demyelination and oligodendrocyte death (Sofroniew and Vinters, 2010; Haroon et al., 2011). Glial Fibrillary Acidic Protein (GFAP) knockout mice revealed more extensive abnormalities in the white matter than in the gray matter (Liedtke et al., 1996).

During development and regeneration, cells from the oligodendrocyte lineage keep in intimate contact with astrocytes that regulate their activity and function (Moore et al., 2011). As such, extensive research has recognized the importance of astrocytes in the modulation of oligodendrocyte proliferation and differentiation (Noble et al., 1988). An increasing wealth of scientific evidence suggests that the astrocytic response determines whether white matter lesions are able to re-myelinate (Barnett and Linington, 2013). Irrespectively, the exact mechanisms by which they affect re-myelination still remain elusive. In this review, we will highlight the features of astrocytes in CNS white matter and address the versatile roles by which astrocytes affect OPCs and/or oligodendrocytes, ultimately determining the degree of myelin repair or re-myelination that occurs following white matter damage.

ASTROCYTES IN WHITE MATTER

Astrocytes are heterogeneous in many aspects, such as development, morphology, location, protein expression and function. They are mainly derived from radial glia in developmental brain and are generated by subventricular stem cells in the adult brain (Tsai et al., 2012). A bipotential progenitor cell population that expresses A2B5 surface marker also can differentiate into either type 2 astrocytes or oligodendrocytes in vitro (Raff et al., 1983). The astrocytes originating from different progenitor cells stay in place and are not replenished by those in neighboring domains (Tsai et al., 2012). Astroglial morphology, density and proliferation independently define the discrete cytoarchitecture of the adult mammalian CNS (Emsley and Macklis, 2006).

Astrocytes in gray matter are typically larger than those in white matter. The main type of astrocytes in gray matter is the protoplasmic astrocyte (designed as type-1 astrocytes), which are bushy or spongiform and possesses numerous highly branched fine processes that spread more or less radially from the soma. At least one of the processes contacts blood vessels via perivascular endfeet. In white matter there mainly are the fibrous astrocytes (designed as type-2 astrocytes), which have less branched and thicker processes with smooth, rough, straight, or undulating appearance and much longer length than protoplasmic astrocytes (Sun et al., 2009). The somas of fibrous astrocytes are often evenly spaced and ranked in rows between the axon bundles, and their processes terminate at nodes of Ranvier, the sites of action potential generation (Butt, 2011).

Neighboring protoplasmic astrocytes have non-overlapping spatial domains with little overlap of neighboring processes (Halassa et al., 2007). They are most evident in the areas of high synaptic density, indicating main participation of astrocytes in modulating synaptic activities in gray matter. Fibrous astrocytes do not have individual spatial domains and...
the processes of neighboring astrocytes overlap extensively, suggesting their supporting or metabolic effects in white matter (Sun and Jakobs, 2012).

Astrocytic densities and proliferation rates vary broadly in different white matter tracts. The density of fibrous astrocytes ranges from virtually zero in the stria terminalis to 100–125 cells/mm² in the optic tract. Corpus callosum, the largest fiber tract in white matter, contains 79 ± 4 GFAP-positive cells/mm². Dentate gyrus has the highest proliferation rate of astrocytes across the adult mammalian CNS, followed by subventricular zone and rostral migratory stream when estimated with bromodeoxouridine (BrdU)/GFAP-positive cells (Emsley and Macklis, 2006).

Astrocytes express intermediate filament proteins depending on their types and developmental stages. GFAP is a kind of characteristic biomarker which is expressed exclusively by astrocytes in the CNS. Up-regulation of GFAP expression under pathophysiological conditions is generally considered as a hallmark of reactive astrocytes (Sofroniew and Vinters, 2010). GFAP, vimentin and nestin are highly expressed in white matter compared to gray matter, so are glutamate-aspartate transporter (GLAST), glutamate transporter-1 (GLT-1) and glutamine synthetase (GS; Goursaud et al., 2009). Elevated GFAP expression may help GLAST anchored in the membrane of reactive astrocytes (Sullivan et al., 2007), indicating astrocytes in white matter have more powerful capacity of glutamate clearance than those in gray matter. The result is in accordance with the metabolic features of oligodendrocyte lineage. Oligodendrocytes eventually have to support membranes up to 100 times the weight of their cell body, which consequently leads to extremely high metabolic rates with the production of many toxic byproducts. However, cells of the oligodendrocyte lineage have only low concentration of the anti-oxidative enzyme glutathione. Effective glutamate clearance and release of glutathione by astrocytes are the major mechanisms preventing accumulation of glutamate and maintaining healthy oligodendrocytes (Kimmelberg and Nedergaard, 2010).

THE EFFECT OF ASTROCYTIC ROLES ON OLIGODENDROCYTE LINEAGE

An Energy Supplier

The adult brain occupies only 2% weight of our body but consumes nearly 20% of glucose and oxygen. There is no direct glucose storage in our brain cells. Under normal physiological conditions, astrocytes and oligodendrocytes take in glucose directly from the surrounding blood vessels through glucose transporter 1(GLUT1). However, during hypoglycaemia or aglycaemia, as well as during the period of increased neural activities, astrocyte-derived glycogen is the main energy source (Brown et al., 2003). Astrocytes are the sole repository for glycogen particles in the mammalian CNS because glycogenesis is confined only to astrocytes (Cataldo and Broadwell, 1986) and also because astrocytic endfeet cover more than 90% of the cerebral vasculature, which makes them absolutely dominant to obtain the glucose. As such, they are the storage site of glycogen (Baltan, 2015).

Astrocytic glycogen is released in the form of lactate by glycolysis on demand, and lactate is transported through monocarboxylate transporter (MCT) to ambient parenchymal cells. Glial cells express both MCT1 and MCT4. MCT1 expression is much more pronounced in oligodendrocytes than astrocytes (Baltan, 2015). As such, this suggests that oligodendrocytes need much lactate via MCT1 from both astrocytes and blood circulation as a source of energy and a precursor of lipids to build carbon skeletons. The oxidative rate of lactate is higher and the rate of lipid synthesis from lactate is at least six-fold higher in oligodendrocytes than in astrocytes or neurons (Sánchez-Abarca et al., 2001; Rinholm et al., 2011). Oligodendrocytes actively utilize lactate by oxidation and lipogenesis which are required to synthesize myelin, a specialized lipid—rich membrane. It has been found that oligodendrocytes are more vulnerable to ischemia or hypoxia than neurons (Pantoni et al., 1996). This may be one of the susceptible reasons that limit their ability to re-myelinate or repair damaged areas of myelin. Fibrous astrocytes in white matter demonstrate very high rates of glucose oxidation through the pyruvate dehydrogenase-catalyzed reaction and through the tricarboxylic acid cycle, while protoplasmic astrocytes in gray matter show high biosynthetic activity (Sánchez-Abarca et al., 2001). However, it is unclear if the priority of astrocytic functions is corresponding to their physiological actions in different regions and as such, this requires further investigative research.

When glucose levels are low, L-lactate, rather than D-lactate is responsible for protecting oligodendrocytes and OPCs and as such rescues myelination from the reduction (Brown et al., 2003; Rinholm et al., 2011). When glucose is sufficient, lactate can also be preferred over glucose as a substrate for myelin production (Rinholm et al., 2011; Baltan, 2015), implying oligodendrocyte lineage may need additional energy and carbon sources even in normal glucose levels. In 1994, the hypothesis of astrocyte—neuron lactate transfer shuttle (ANLTS) was proposed, stating lactate released from astrocytes through glycolysis could be directed one-way traffic via MCTs from astrocytes to neurons (Pellerin and Magistretti, 1994). This begged the question as to whether there is a similar “lactate shuttle” in white matter. Astrocytes can deliver lactate to axons at the site of nodes of Ranvier (Baltan, 2015). It has been found that oligodendrocytes in vitro and in vivo don’t consume but rather are a potential source of lactate to support axon function. These findings indicate or suggest the involvement of a myelin—independent mechanism of axon loss (Fuchschiing et al., 2012). Whether there is lactate shuttle between astrocytes and oligodendrocytes and how they inter-coordinate to supply the lactate to axons are worthy of much attention.

A Participant of Immunological and Inflammatory Functions

There is growing evidence that demonstrates astrocytes work as a kind of immune cells. They take part in formation of BBB, secrete cytokines and inflammatory mediators, regulate...
functions of microglia/macrophage cells, as well as present antigen via major histocompatibility complex and indirect or direct phagocytosis. Various observations strongly suggest that astrocytes participate in two-way communications with immune and inflammatory cells and thereby play an irreplaceable role in regulating CNS immune and inflammatory reactions (Hamby et al., 2012; Sofroniew, 2014), depending on different triggered signaling pathways, locations and times.

Transcription factor nuclear factor kappa B (NF-κB) appears to have an important role in understanding the inflammatory effect of astrocytes on oligodendrocytes. Transgenic technology (especially the deletion experiments) represents a new in vivo tool that is being used to advance our understanding of the role of NF-κB on astrocytes and oligodendrocytes. For example, a mouse model of GFAP—IkBα—dominant-negative (dn) is made by inactivating NF-κB in astrocytes through overexpression of a dn form of the NF-κB super repressor (IkBα-dn) under control of the GFAP promoter. In this model oligodendrocytes are protected via reduced immune-cell infiltration (Brambilla et al., 2014) and downregulation of adhesion molecules and chemokines (Brambilla et al., 2009) at acute or chronic stage of experimental autoimmune encephalomyelitis (EAE). These molecules and chemokines include macrophages/granulocytes (CD45+CD11b), MHCI+ macrophages/granulocytes, B cells (B220), activated B cells (B220MHCI), natural killers (NK1.1), CD4 T cells, ICAM-1, VCAM-1, Itg-β5, Itg-β7, CXCL9, CXCL10 and their receptor CXCR3 etc. At 6 days after inducing re-myelination of EAE model in GFAP—IkBα—dn mice, increased oligodendrogenesis, rather than the number change of OPCs, is distributed around the epicenter. It suggests the anti-inflammatory niche near the lesion in GFAP—IkBα—dn group is more permissive for the differentiation of OPCs into mature oligodendrocytes (Brambilla et al., 2009). Conditional deletion of related factors in astrocytic NF-κB pathways, such as Act1 (Raasch et al., 2011; Kang et al., 2013b), IkB kinase 2 (Raasch et al., 2011), NEMO (van Loo et al., 2006) and so on, lead to its inactivity thereby exert protective influence on the cells of oligodendrocyte lineage through inhibiting the release of pro-inflammatory factors. Laquinimod (LAQ), a new oral immunomodulatory compound for relapsing and remitting multiple sclerosis (RRMS), can ameliorate myelin injury via down-regulating NF-κB activation in astrocytes rather than in microglia in vivo and in vitro (Brück et al., 2012).

Chemokines represent another well-known molecular cue expressed by astrocytes that affect oligodendrocyte biological behavior. Astrocyte-conditioned media collected from astrocytes pre-exposed to pro-inflammatory supernatants lead to reduced OPCs differentiation without increasing cell death obviously through astrocyte-derived CXCL10 (Moore et al., 2015). Deletion of astrocytic CXCL10 delay clinical onset but doesn’t affect progressive axon loss in EAE mice (Mills Ko et al., 2014). Astrocytes transiently express a high level of CXCL1 during the spinal cord development, and CXCL1-mediated signaling through its receptor CXCR2 on OPCs promote their proliferation via a platelet-derived growth factor (PDGF)-AA-driven mechanism and inhibit migration (Tsai et al., 2002). The mice models with conditional gene deletion of CCL2 (also as monocyte chemoattractant protein-1, MCP-1) from astrocytes have less severe EAE late in disease and slow progression of spinal cord axon loss, involving significantly decreasing accumulation of classically activated M1 microglia (Moreno et al., 2014), less macrophage and T cell inflammation (Kim et al., 2014), the lack of leukocyte penetration and disrupted claudin -5 at the BBB in CNS (Paul et al., 2014). However, the effects of CCL2 deletion in astrocytes on acute stage or onset of EAE are discrepant and warrant further researches (Kim et al., 2014; Moreno et al., 2014).

### A Source of Trophic Factors and Iron

Astrocytes secrete many tropic factors which affect oligodendrocyte lineage during development and remyelination and are an indispensable part of astrocytic anti-inflammatory function. Astrocytes are the main producer of PDGF (Kernt et al., 2010) which could be enhanced by IFN-γ, IL-5 and IL-17 (Moore et al., 2015) in CNS, suggesting the secretion of astrocyte-derived PDGF can be regulated by inflammatory stimulations. PDGF is an important survival factor for OPCs and stimulates OPCs to either proliferation or differentiate into mature oligodendrocytes, depending on the developmental stage of the progenitor cells (Gard et al., 1995). Although astrocyte-derived PDGF increases OPCs density either in development or in focal demyelinated lesions, there is no difference in the time course or extent of remyelination between PDGF-increased group and wild-type group (Woodruff et al., 2004), indicating the availability of OPCs isn’t the critical limitation of remyelination.
Fibroblast growth factor-2 (FGF-2), expressed by both neurons and glia during development, mainly comes from astrocytes after myelin injury (Messersmith et al., 2000). It is a potent mitogen for OPCs and most of the time, related to successful re-myelination (Messersmith et al., 2000; Albrecht et al., 2003; Hesp et al., 2015). However, application of FGF-2 sometimes becomes a handicap for myelin repair. FGF-2 in combination with PDGF promotes OPCs renewal but prevents their differentiation (Clarner et al., 2011; Ogata et al., 2011). Elevated FGF-2 leads to severe disruption of mature oligodendrocytes and a marked loss of myelin (Butt and Dinsdale, 2005) or even converts mature oligodendrocytes to a novel phenotype (Bansal and Pfeiffer, 1997). How astrocytic FGF-2 exerts its influence hinges on the status of oligodendrocyte lineage.

Ciliary neurotrophic factor (CNTF) is produced by astrocytes and neurons in the CNS. It is an important survival factor for oligodendrocytes, promotes OPCs differentiation into mature myelin-forming cells, helps differentiated oligodendrocytes to synthesize myelin and protects oligodendrocytes from inflammatory insult (Stankoff et al., 2002; Modi et al., 2013). Insulin-like growth factor-1 (IGF-1) is widely expressed in the CNS and its expression in astrocytes is increased during and after variety of CNS injuries (Lee et al., 1996). Astrocytic IGF-1 promotes significant increase in the number of oligodendrocytes and myelin in vivo by directly affecting IGF type 1 receptor (IGF1R) signaling in the cells of oligodendrocyte lineage during normal oligodendrocyte development and myelination (Zeger et al., 2007). IGF also contributes OPCs survival and augments differentiation (Zumkeller, 1997). Leukemia inhibitory factor (LIF) expressed by astrocytes is low or undetectable in normal adult tissue (Aloisi et al., 1994). It is increased by TNFR2-mediated activation of the PI3K-PKB/Akt pathway in primary astrocytes, promoting OPCs differentiation into mature myelinating oligodendrocytes (Fischer et al., 2014). Astrocytes release LIF in response to ATP liberated from axons firing action potentials, which promotes myelination by mature oligodendrocytes (Ishibashi et al., 2006). However, LIF is not always beneficial for oligodendrocyte lineage. It inhibits myelination in a manner of concentration-dependent biological activity (Ishibashi et al., 2006; Fischer et al., 2014).

There are many other trophic factors affecting myelination secreted by astrocytes, including bone morphogenetic proteins (BMP; Wang et al., 2011), neuregulin (Viehover et al., 2001), brain-derived neurotrophic factor (BDNF; Fulmer et al., 2014), osteopontin (Selvaraju et al., 2004) as well as others (as summarized in Table 1). Different trophic factors from astrocytes exert influence on myelination and repair directly or indirectly via autocrine or paracrine.

Iron is indispensable in mammalian metabolism because it acts as a co-factor in many metabolic reactions and participates in the formation of heme and iron-sulfur clusters. However, most of brain cells can’t get iron directly from the blood.

### Table 1 | The effect of astrocyte-derived factors on oligodendrocyte lineage or EAE.

| Astrocyte-derived factors | Model | Effect on oligodendrocyte lineage or EAE | Reference |
|---------------------------|-------|-----------------------------------------|-----------|
| CXCL1                     | Spinal cord | Inhibiting OPCs migration and promoting OPCs proliferation | Tsai et al. (2002) |
| CCL2                      | MOG-induced EAE | Reducing acute and long-term severity of clinical deficits; Exacerbating severity of EAE at late stage | Brambilla et al. (2009); Moreno et al. (2014); and Paul et al. (2014) |
| CXCL10                    | MOG-induced EAE | Be related with clinical onset of EAE | Mills Ko et al. (2014) |
| IL-6                      | Astrocyte-conditioned media pre-exposed to the proinflammatory supernatants | Reducing OPCs differentiation without an apparent increase in cell death | Moore et al. (2015) |
| IL-1β                     | Hypoxic PWMD | Inducing oligodendrocyte apoptosis | Deng et al. (2014) |
| BDNF                      | Cuprizone-induced demyelination | Reversing deficits elicited following demyelination | Fulmer et al. (2014) |
| BMP                       | Spinal cord injury | Inhibiting OLs differentiation | Wang et al. (2011) |
| CNTF                      | Spinal cord injury | A pro-OLs differentiation and survival factor | Hesp et al. (2015) |
| FGF-2                     | Murine hepatitis virus-induced demyelination of the spinal cord | A potent mitogen for OPCs | Albrecht et al. (2003) |
| IGF-1                     | Primary cultured astrocytes | Promoting OPCs maturation | Clarner et al. (2011) |
| LIF                       | Astrocyte-oligodendrocyte coculture model | Promoting OLs Maturation | Ishibashi et al. (2006) and Fischer et al. (2014) |
| Neuregulin                | Mice bearing a null mutation in the neuregulin gene | Be necessary for the normal development of OLs | Viehover et al. (2001) |
| Osteopontin               | Cuprizone-induced demyelination | Inducing proliferation of OPCs | Selvaraju et al. (2004) |
| PDGF                      | Cuprizone-induced demyelination in mice | Increasing OPCs population density | Woodruft et al. (2004) |
| Hyaluronan                | Lysochelatine or MOG-induced EAE | Inhibiting OPCs maturation | Back et al. (2005) |
| Fibronectin, vitronectin, and laminin combined with bFGF | Mixed culture containing human OLs, astrocytes, or microglia | Promoting process outgrowth by adult human OLs | Oh and Yong (1996) |
circulation because of the existence of BBB. Astrocytes are considered as a key regulator of iron in the CNS due to their extensively distributed endfeet, which almost completely covers the brain capillaries which have overwhelming location advantages to acquire iron. Numerous receptors and transporters are involved in the uptake, distribution and release of iron. Through these mediators, holo-transferrin that is the main form of iron in the systemic bloodstream enters the cytosol through endocytosis and is released in the form of ferrous iron (Fe^{2+}) into cytoplasm and then into intercellular fluid. Fe^{2+} is converted to Fe^{3+} by the enzymes on the surface of astrocytes and then binds to apo-transferrin (that is, iron-free transferrin) mainly synthesized and secreted by oligodendrocytes and cells of the choroid plexus (Zakin et al., 2002). In addition, astrocytes have been shown to accumulate non-transferrin-bound iron (NTBI) from Fe^{2+} (Zakin et al., 2002; Tulpule et al., 2010) and Fe^{3+} (Philpott, 2012; Figure 1).

Of all the cell types in the brain, oligodendrocytes contain the highest level of immobilized, protein-bound iron (Todorich et al., 2009). During development, a peak period of iron influx into the brain coincides with the time point of the maximum amount of myelin production (Crowe and Morgan, 1992). However, iron may affect oligodendrocyte development during early more than late embryogenesis (Morath and Mayer-Pröschel, 2001). In adult brain, oligodendrocytes have high demand for iron reflected by their high levels of ferritin and basic requirement for their functions, oxidative metabolism and remyelination (Todorich et al., 2009). Oligodendrocytes are unable to synthesize iron, so they must obtain it from the ambient environment.

Ferritin is the main storage form of iron in the CNS. Microglia exhibits stronger stain for ferritin (Connor et al., 1990) while astrocytes express low ferritin level (Todorich et al., 2005) under physiological conditions, indicating astrocytes are vital for the iron transportation, not the storage. As a kind of cells connecting directly with circulating iron, the damage to any part of astrocytic iron transportation may have an influence on oligodendrocyte lineage. The astrocyte-specific FPN knockout demyelinating-mouse induced by lysosolchin microinjection produces a clear decrease in proliferation of OPCs, leading to reduced remyelination. Lack of iron reduces the secretion of pro-inflammatory cytokines (i.e., IL-1 and TNF-α) from microglia, therefore resulting in down-regulation of FGF-2 and IGF-1 generated by IL-1-stimulating and TNF-α-stimulating astrocytes, respectively (Schulz et al., 2012). Furthermore, even though iron is supplemented after a period of iron-deprivation to the normal serum level, morphological damage of myelin from iron-deficiency is not easily reversed by iron reposition (DeMaman et al., 2008). In a demyelinating rat induced by myelin mutant, iron accumulation, expression of ferritin and antioxidant enzyme heme oxygenase-1 (HO-1) in astrocytes are increased, indicating a protective reaction of astrocytes to alleviate iron-mediated cytotoxicity by regulating autologous iron-related pathway (Izawa et al., 2010). Taken together, astrocytes act as a direct gaining of iron in the CNS and demonstrate pivotal effects on oligodendrocyte lineage with high demand for iron.

### A Sustainer of Homeostasis

Oligodendrocyte lineage is highly vulnerable to the excitatory neurotransmitter glutamate because of abundant glutamate receptors on cell surface and low content of reduced glutathione (Sánchez-Gómez et al., 2011). Astrocytes express high levels of glutamate transporters-excitatory amino acid transporters 1 (EAAT1, also as GLAST) and EAAT2 (also as GLT-1). Astrocytic uptake of glutamate is the major mechanism preventing accumulation of glutamate in the extracellular space and thus protecting oligodendrocyte lineage from excessive activation and excitotoxic cell death. They take in glutamate and release glutamine (glutamate-glutamine cycle), take in glutathione precursors and release glutathione (Kimelberg and Nedergaard, 2010). The loss of glial GLAST or GLT-1 produces elevated extracellular glutamate levels. Decreased uptake of glutamate by astrogial EAATs causes oligodendroglia death in hypoxic PWMD (Murugan et al., 2013). The activation of mammalian target of rapamycin (mTOR)-Akt-NF-γB signaling cascade, which promotes glutamate uptake by up-regulation of astrocytic GLT-1, may be potential protection (Ji et al., 2013). In addition, glutamine is an important component of proteins and an excellent energy substrate. However, oligodendrocytes do not have GS and require glutamine from astrocytes.

Astrocytes are a key regulator of ions and water producing a permissive microenvironment for development and survival of oligodendrocyte lineage. Physical contacts of gap junctions between astrocytes and oligodendrocytes form panglia syncytium supporting a unidirectional flow of cytosolic contents from astrocytes to oligodendrocytes. The major function of this coupling is to provide potentially K⁺ spatial buffering and serves to dissipate the increased K⁺ concentration in oligodendrocytes via direct flow into astrocytic cytoplasm (Kofuji and Newman, 2004). Na⁺/H⁺ exchanger (NHE) is the most important plasma membrane transporter involved in the astrocytic pH regulation. Blocking NHE1 activity by the potent NHE1 inhibitor HOE-642 significantly reduces the resting level of intracellular pH in NHE1⁻/⁻ astrocytes (Kintner et al., 2004). After hypoxia or ischemia, NHE-1 protein is up-regulated in astrocytes and inhibition of NHE-1 is neuroprotective by ameliorating disruption of ionic homeostasis (Cengiz et al., 2011).

All transmembrane ionic shifts and membrane transport mechanisms such as glutamate uptake are followed by water movement. Unbalance of the level of extracellular ions and neurotransmitters activates astrocytic regulatory volume changes, resulting in the shrinkage or swelling of astrocytes (Benesova et al., 2009). Aquaporin4 (AQP4) water channels expressed in the perivascular end-feet of astrocytes contribute to water homeostasis by regulating water transport and are involved in several disease pathways (Amiry-Moghaddam et al., 2003). In an ischemic stroke model, the presence of AQP4 was shown to aggravate post-ischemic cytotoxic edema, while AQP4-KO mice demonstrated an improved neurological outcome (Wang W. W. et al., 2014). Neuromyelitides optica (NMO) is a representative condition of inflammatory demyelinating disorder caused by targeting astrocytic AQP4. As such, this indicates that direct damage to astrocytes can influence the integrity of oligodendrocyte-myelin unit.
Iron metabolism and transport in blood-brain barrier (BBB).

The above sketch demonstrates ultrastructure of BBB. The bottom figure shows how iron metabolizes and is transported between the structures of BBB. Two atoms of ferric iron ($Fe^{3+}$) are bound to one transferrin (Tf) molecule to generate holo-transferrin, which is the main form of iron in the systemic bloodstream. Holo-transferrin interacts with surface cellular transferrin receptor 1 (TfR1) and then enters the cytosol through endocytosis. STEAP3, the endosomal metallo-reductase, reduces insoluble $Fe^{3+}$ to soluble ferrous iron ($Fe^{2+}$) which is released into cytoplasm via divalent metal transporter 1 (DMT1) and then into intercellular fluid mediated by ferroportin 1 (FPN1). $Fe^{2+}$ is converted to $Fe^{3+}$ by the enzyme of ceruloplasmin (CP), a kind of ferroxidase, which is attached to the membrane by glycosyl phosphatidylinositol (GPI). $Fe^{3+}$ combines with apo-transferrin (iron-free transferrin) which is mainly synthesized and secreted by oligodendrocytes and cells of the choroid plexus, and then enters the endfoot of astrocytes by endocytosis. In endosome $Fe^{3+}$ is also reduced to $Fe^{2+}$ by STEAP3 and then released to the astrocytic cytoplasm. In addition, astrocytes are also able to obtain iron from other sources. Haem-bound $Fe^{3+}$ uptake is mediated by heme carrier protein 1 (HCP1) and $Fe^{3+}$ is liberated from internalized heme by heme oxygenase-1 (HO-1). $Fe^{3+}$ can be taken up by a kind of unknown $Fe^{3+}$ transporter, $Fe^{2+}$ can be transported into astrocytes via DMT1 directly. $Fe^{3+}$ and $Fe^{2+}$ transform into each other as needed in astrocytic cytoplasm. They may be released to outside of the astrocytes by FPN1 ($Fe^{2+}$), stored in ferritin ($Fe^{3+}$) or enter the mitochondria by mitoferrin which are the mitochondrial iron transporters, where iron can be used for incorporation into heme groups and iron-sulfur (Fe–S) clusters.

Many studies have shown how astrocyte-secreted extracellular matrix (ECM) affects the behavior of oligodendrocyte lineage, particularly OPCs. Astrocyte-derived hyaluronan may inhibit OPC maturation (Back et al., 2005), leading to re-myelination failure. However, astrocytic ECM containing fibronectin, vitronectin, and laminin combined with bFGF is found to...
promote oligodendroglial process extension in vitro (Oh and Yong, 1996). Astrocytic secretion changes the components of ECM, thereby adjusts a favorable or adverse surrounding environment of re-myelination, depending on the protein composition and the receptors on the OPCs. In summary, astrocytes are a pivotal controller for homeostasis, thus extensively influence oligodendrocyte lineage.

ASTROCYTES IN WHITE MATTER PATHOLOGY

Demyelinating Diseases

As mentioned above, NMO is a typical demyelinating disorder induced by direct autoimmune damage to astrocytic AQP4. Recently there is a new group of clinical features with positive AQP4 antibodies which is termed NMO spectrum disorder (NMOSD) with restricted disorders, including recurrent optic neuritis, relapsing transverse myelitis and some encephalitic/brainstem presentations (de Seze and Collongues, 2013). NMOSD is characteristic of positive serum AQP4-antibody and makes it easy to find demyelinating diseases caused by astrocytic impairments more frequent. Alexander disease is another example of how astrocytic dysfunction directly compromises myelination. It occurs ranging from early infanthood to mid-life and causes developmental retardation and seizures. It is a rare non-familial leukodystrophy, primarily caused by mutations in the gene encoding GFAP of astrocytes with associated increases in GFAP, the accumulation of Rosenthal fibers and loss of myelin (Messing et al., 2012). In the process of pathogenesis, normal protoplasmic astrocytes are converted to severe “reactive” astrocytes displaying activation of mTOR cascade, acquirement of CD44, loss of GLT-1 and diminished glutamate transporter current (Sosunov et al., 2013). As such, this indicates that the dysfunctions of astrocytic morphology and physiology make themselves uncoupled to adjacent astrocytes and detrimental to neighboring oligodendrocytes.

Multiple sclerosis (MS) is a representative of primary demyelinating diseases. The hypothesis that MS is primarily caused by astrocytic dysfunction is dated back to 1904. However, their actual influence on MS still remains unclear. In recent decades, mounting evidence shows astrocytes play controversial roles in MS development and pathogenesis. Astrocytes in MS take part in spontaneous myelin repair by secreting trophic factors and providing energy and substrates, such as lactate and iron, to myelin and axons (reviewed by Moore et al., 2011). However, they also contribute to myelin degradation and release pro-inflammatory and inhibitory factors to block this process (Durfinova et al., 2014). In chronic MS lesions, remyelination is absent or mainly in the plaque border because of the formation of hypertrophic astrocytes, scarring fibrous astrocytes or even astrocytic glial scar (Clemente et al., 2013) that inhibit OPCs migration into the lesions thereby preventing their differentiation into mature oligodendrocytes (Bramow et al., 2010). In general, astrocytes in the acute phase are crucial for recovery, while their presence in the chronic phase is inhibitory. Interestingly, MS patients seem to show higher risk of vascular disease compared with those without MS (Durfinova et al., 2014), and are more likely to be hospitalized for ischemic stroke than ischemic heart disease or myocardial infarction (Allen et al., 2008), especially within the first year after a first-time MS diagnosis (Christiansen, 2012). It may be related to endothelial dysfunction whose pathological mechanism is possibly linked to a loss of β2 adrenergic receptors on astrocytes of MS demyelinating lesions (Durfinova et al., 2014).

Neurodegenerative Diseases

There is a group of distinctive iron-overloaded disorders known as neurodegeneration with brain iron accumulation (NBIA) diseases involved with nine identified disease genes. Among them, aceruloplasminaemia is directly caused by abnormal iron metabolism mainly in astrocytes. It is characteristic of iron excess accumulation caused by gene mutations in the brain and visceral organs, such as liver and pancreas, with a triad of retinal degeneration, diabetes mellitus and brain dysfunction, such as dystonia, ataxia, dementia and depression (Skidmore et al., 2008). Astrocytic ceruloplasmin (CP) is required for iron export from astrocytes to oxidize Fe2+ to Fe3+, which can bind to extracellular transferring (Figure 1). The functional loss of CP leads to marked iron overload in astrocytes and iron deficiency in surrounding parenchymal cells, for example, oligodendrocytes. Furthermore, iron-overloaded astrocytes also damage ambient parenchymal cells by releasing toxic factors.

Alzheimer’s disease (AD) is the most common form of progressive neurodegeneration in the elderly with the major histopathological hallmarks of extracellular amyloid-β (Aβ) protein accumulation (known as senile plaques) and intracellular neurofibrillary tangles (known as abnormal phosphorylation of tau-protein filaments). At the early stage of AD, astrocytes show atrophy with decreased GFAP-positive area and the reduction in the somatic size and the number of primary processes (Kulijewicz-Nawrot et al., 2012). However, at the late stage of AD, astrogliosis is found widespread with cellular hypertrophy and increases in the number of GFAP and S100β protein (Olabarria et al., 2011). The interaction between astrocytes and Aβ is changeable. Astrocytes contribute to the clearance and degradation of Aβ (Nielsen et al., 2009) and a reduced astrocytic response to Aβ plaques is associated with cognitive impairment, demonstrating relative resistance to Aβ toxicity, at least partly through astrocytic glycolysis (Fu et al., 2015), or on the contrary, astrocytes become an extra source of Aβ (Hennek et al., 2005). It has been reported that Aβ-induced oligodendrocyte apoptosis might be a critical initiating step in AD (Roth et al., 2005). As such, astrocytes have an influence on Aβ metabolism which works in Aβ-induced oligodendrocyte-related AD pathology. This suggests that astrocytes may affect effectively oligodendrocytes via Aβ pathways in AD. However, further research in this area is required before definitive conclusions can be drawn.
Amyotrophic lateral sclerosis (ALS) is another “classic” neurodegenerative disorder which is characterized by the progressive loss of corticospinal and spinal motor neurons and involved in progressive reactive astrogliosis and reduction in myelin. ALS is presented with definite white matter pathology, and further researches have shown oligodendrocytes play an early role in ALS, even start to degenerate before motor neurons (Kang et al., 2013a). Oligodendrocyte lineage attempts to compensate for oligodendrocyte loss by increasing their proliferation and differentiation rates (reviewed by Nonneman et al., 2014) but fails because of a loss of MCT1 (Lee et al., 2012), mutant SOD1 or being a direct target of this disease (Stieber et al., 2000). As a kind of cell type with multiplicity and complexity, it is reasonable to speculate astrocytic alterations importantly influence various neuropathological conditions, including ALS. Riluzole, the only FDA-approved drug for ALS, has been found enhancing astrocytic glutamate uptake by up-regulating GLT-1 level and activity (Carbone et al., 2012) and stimulating astrocytic syntheses of NGF, BDNF and GDNF (Mizuta et al., 2001). The ALS model of ablating mutant SOD1 expression selectively in astrocytes doesn’t affect onset, but sharply slows later disease progression (Yamanaka et al., 2008). The evidence indicates damage of oligodendrocyte lineage mainly occurs before or at the onset of ALS, while astrocytes exert their influence during the course of disease.

### Psychiatric Disorders

Mounting literature has displayed the close relation between the lesions of white matter or oligodendrocyte lineage and psychiatric disorders, including schizophrenia, bipolar disorder, depression and autism (Haroutunian et al., 2014). In these diseases, astrocytic changes of physiology and functions have the potential to affect complex behavior and mood. The number of astrocytes in postmortem histological studies of schizophrenia is controversial. Some authors reported no change (Damadzic et al., 2001) while others found increased (Schnieder and Dwork, 2011) or decreased number (Hercher et al., 2014). Fibrillary astrocytes mainly account for the reduced number (Williams et al., 2014), and that the area fraction of GFAP-positive astrocytes decreases and astrocytic spatial distribution demonstrates increased cell clustering in white matter of schizophrenia patients (Hercher et al., 2014). These disparities may be explained, at least in part, by heterogeneity of schizophrenia symptoms and the differences of staining methods and selected markers for assessing the number of astrocytes.

The disturbance of neurotransmission, especially the glutamatergic transmission, may be one of the leading pathological mechanisms of schizophrenia (Laruelle, 2014). As mentioned above, astrocytes are crucial for the sustenance of glutamatergic transmission. Deletion of adenosine A2A receptors in astrocytes disrupts glutamate homeostasis by controlling GLT-1 activity, which is relevant to schizophrenia (Matos et al., 2015). Mutant disrupted-in-schizophrenia 1 (DISC1) in astrocytes reduces the production of D-serine, resulting in compensatory changes in the levels of the amino acid transporters and N-methyl-D-aspartate receptors in the context of tripartite synapse (Abazyan et al., 2014). The EAAT2 expression is reduced in subjects with high-risk metabotropic glutamate receptor 3 haplotype associated with schizophrenia (Spangaro et al., 2012). It is indicated that glutamatergic metabolism in astrocytes may be a potential therapeutic target for schizophrenia.

Actually, many anti-psychiatric drugs take effect through activation of astrocytic pathways but seemingly not including venlafaxine (Zimmermann et al., 2012; Wang J. et al., 2014). Fluoxetine, an anti-depressive drug and one of serotonin-specific reuptake inhibitors (SSRIs), acutely stimulates glycogen synthesis via AKT phosphorylation (Hertz et al., 2014) and also affects glycogenolysis (Xu et al., 2013) in astrocytes. However, chronic treatment with fluoxetine may cause the changes of gene expression in astrocytes (Hertz et al., 2014). Paroxetine, amitriptyline and imipramine affect DNA methyltransferase-1 activity via G9a in primary astrocytes (Zimmermann et al., 2012). The chronic treatment with lithium, carbamazepine and valproic acid results in a gradual development of intracellular alkalination caused by stimulation of acid extruders in astrocytes (Hertz et al., 2014), which alters their functions and may be associated with the fluctuation of pharmacological effects. Altogether, astrocytes are a promising target for the therapy of psychiatric disorders and worthy of further investigations.

### CONCLUSIONS AND FUTURE PERSPECTIVES

It is still poorly understood how astrocytes impact oligodendrocyte lineage and how signals released or expressed by astrocytes affect re-myelination. We have confirmed that reactive astrogliosis is not a simple all-or-none cellular transformation after stimulation based on previous studies. It is a continuum of changes ranging from reversible alterations in gene expression and cell hypertrophy to scar formation with permanent tissue rearrangement both in vivo and in vitro. These responses are graded, depending on the nature and severity of the insult. After white matter injury, the effect that astrocytes exert on oligodendrocyte lineage is changeable with different reactive conditions, for example, time points, stimuli, signaling pathways represent a few ways for this to occur. Inhibiting specifically detrimental signaling pathways in astrocytes while preserving their beneficial functions may be a promising approach.

Most of the conducted research is concerned with the astrocytic effect on oligodendrocyte lineage or white matter pathology through the use of rodents to mimic human myelin-related disorders. Although some of the research in this area demonstrates hopeful prospects, the reality is that these interventional approaches are not applicable to repairing damaged myelin in the human body. Although the gross morphology of astrocytes is similar to those in rodents, human astrocytes have larger diameter, longer and thicker processes, more GFAP immunoreactions and more complicated synapses, which results in a 16.5-fold increase in astrocytic volume of human brains (Oberheim et al., 2009; Han et al., 2013). In addition, the astrocytic diversity further complicates this issue and leads to the difficulties in interventional pharmacological approaches.
targeting. It is necessary to consider the heterogeneity of astrocytes and determine the functional implications of astrocytic reactivity in a context-specific manner. Interventions for demyelinating diseases by manipulating astrocytes open new therapeutic vistas and provide potential pharmacological targets.

AUTHOR CONTRIBUTIONS

JK and XB provided the idea of this work and designed the structure of the manuscript. JL and LZ wrote the manuscript.

REFERENCES

Abazyan, S., Yang, E. J., Abazyan, B., Xia, M., Yang, C., Rojas, C., et al. (2014). Mutant disrupted-in-schizophrenia 1 in astrocytes: focus on glutamate metabolism. J. Neurosci. Res. 92, 1659–1668. doi: 10.1002/jnr.23459

Albrecht, P. J., Murtie, J. C., Ness, J. K., Redwine, J. M., Enterline, J. R., Armstrong, R. C., et al. (2003). Astrocytes produce CNTF during the remyelination phase of viral-induced spinal cord demyelination to stimulate FGF-2 production. Neurobiol. Dis. 13, 89–101. doi: 10.1016/S0969-9610(03)00019-6

Allaman, I., Belanger, M., and Magistretti, P. J. (2011). Astrocyte-neuron metabolic relationships: for better and for worse. Trends Neurosci. 34, 76–87. doi: 10.1016/j.tins.2010.12.001

Allen, N. B., Lichtman, J. H., Cohen, H. W., Fang, J., Brass, L. M., and Alderman, M. H. (2008). Vascular disease among hospitalized multiple sclerosis patients. Neuropediatrics 39, 234–238. doi: 10.1159/000128103

Aloisi, F., Rosa, S., Testa, U., Bonsi, P., Russo, G., Peschle, C., et al. (1994). Regulation of leukemia inhibitory factor synthesis in cultured human astrocytes. J. Immunol. 152, 5022–5031.

Amary-Moghaddam, M., Otsuka, T., Hurn, P. D., Traystman, R. J., Haug, F. M., Froehner, S. C., et al. (2003). An alpha-syntrophin-dependent pool of AQP4 in astroglial end-feet confers bidirectional water flow between blood and brain. Proc. Natl. Acad. Sci. U S A 100, 2106–2111. doi: 10.1073/pnas.0312797100

Attwell, D., Buchan, A. M., Charpak, S., Lauritzen, M., Maccivier, B. A., and Newman, E. A. (2010). Glial and neuronal control of brain blood flow. Nature 468, 232–243. doi: 10.1038/nature09613

Back, S. A., Tuohy, T. M., Chen, H., Wallingford, N., Craig, A., Struve, J., et al. (2005). Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat. Med. 11, 966–972. doi: 10.1038/nm1279

Baltan, S. (2015). Can lactate serve as an energy substrate for axons in good times and in bad, in sickness and in health? Metab. Brain Dis. 30, 25–30. doi: 10.1007/s11011-014-9595-3

Bansal, R., and Pfeiffer, S. E. (1997). FGF-2 converts mature oligodendrocytes to a novel phenotype. J. Neurosci. Res. 50, 215–228. doi: 10.1002/(SICI)1097-4547(19971015)50:2<215::AID-JNR10>3.0.CO;2-7

Barrett, S. C., and Linnington, C. (2013). Myelination: do astrocytes play a role? Neuroscientist 19, 442–450. doi: 10.1177/1073858812465655

Benesova, J., Hock, M., Buitenko, O., Prajerova, I., Anderova, M., and Chvatal, A. (2009). Quantification of astroglial volume changes during ischemia in situ reveals two populations of astrocytes in the cortex of GFAP/EGFP mice. J. Neurosci. Res. 87, 96–111. doi: 10.1002/jnr.21828

Brambilla, R., Morton, P. D., Ashbaugh, J. J., Karmally, S., Lambertsen, K. L., and Bethea, J. R. (2014). Astrocytes play a key role in EAE pathophysiology by modulating macrophage function. Exp. Neurol. 252, 452–467. doi: 10.1016/j.expneurol.2012.12.001

Brambilla, R., Persaud, T., Hu, X., Karmally, S., Shestopalov, V. I., Dvoriantchikova, G., et al. (2009). Transgenic inhibition of astroglial NF-κB improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation. J. Immunol. 182, 2628–2640. doi: 10.4049/jimmunol.0802954

Bramow, S., Frischer, J. M., Lassmann, H., Koch-Henriksen, N., Lucchinetti, C. F., Sorensen, P. S., et al. (2010). Demyelination versus remyelination in progressive multiple sclerosis. Brain 133, 2983–2998. doi: 10.1093/brain awq250

Brown, A. M., Tekkó, S. B., and Ransoms, B. R. (2003). Glycogen regulation and functional role in mouse white matter. J. Physiol. 549, 501–512. doi: 10.1113/jphysiol.2003.042416

Bruck, W., Pförtner, R., Pharm, T., Zhang, J., Hayardeny, L., Piryatinsky, V., et al. (2012). Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 124, 411–424. doi: 10.1007/s00401-012-1009-1

Butt, A. M. (2011). ATP: a ubiquitous gliotransmitter integrating neuron-glial networks. Semin. Cell Dev. Biol. 22, 205–213. doi: 10.1016/j.semcdb.2011.02.023

Butt, A. M., and Dinsdale, J. (2005). Fibroblast growth factor 2 induces loss of adult oligodendrocytes and myelin in vivo. Exp. Neurol. 192, 125–133. doi: 10.1016/j.expneurol.2004.11.007

Carbone, M., Duty, S., and Rattray, M. (2012). Riluzole elevates GLT-1 activity and levels in striatal astrocytes. Neurochem. Int. 60, 31–38. doi: 10.1016/j.neuint.2011.10.017

Cataldo, A. M., and Broadwell, R. D. (1986). Cytochemical identification of cerebral glycogen and glucose-6-phosphate activity under normal and experimental conditions. II. Choroid plexus and ependymal epithelium, endothelia and pericytes. J. Neurocytol. 15, 511–524. doi: 10.1007/bf01611733

Cengiz, P., Klemen, N., Uluc, K., Kendigelen, P., Hagemann, T., Actue, E., et al. (2011). Inhibition of Na+H+ exchanger isoform 1 is neuroprotective in neonatal hypoxic ischemic brain injury. Antioxid. Redox Signal. 14, 1803–1813. doi: 10.1089/ars.2010.3468

Christiansen, C. F. (2012). Risk of vascular disease in patients with multiple sclerosis: a review. Neurol. Res. 34, 746–753. doi: 10.1177/1743132812Y.000000051

Clarke, I. E., and Barres, B. A. (2013). Emerging roles of astrocytes in neural circuit development. Nat. Rev. Neurosci. 14, 311–321. doi: 10.1038/nrn3484

Clarrer, T., Parabucki, A., Beyer, C., and Kipp, M. (2011). Corticosteroids impair remyelination in the corpus callosum of cuprizone-treated mice. J. Neuroendocrinol. 23, 601–611. doi: 10.1111/j.1365-2826.2011.02140.x

Clemente, D., Ortega, M. C., Mejero-Jerez, C., and de Castro, F. (2013). The role of the TGF-β family in gliogenesis during brain development and in demyelinating diseases. Front. Cell. Neurosci. 7:268. doi: 10.3389/fncel.2013.00268

Connor, J. R., Menzies, S. L., St Martin, S. M., and Muñoz, E. J. (1999). Cellular distribution of transferrin, ferritin and iron in the brain of normal and iron deficient rats. Brain Res. 899, 3–15. doi: 10.1111/j.1365-2826.2011.02140.x

Crowe, A., and Morgan, E. H. (1992). Iron and transferrin uptake by brain tissue. J. Neurosci. Res. 33, 2983–2998. doi: 10.1002/jnr.10438

FUNDING

This work was supported by the National Natural Science Foundation (Project Nos: 30900474 and 81200225).

ACKNOWLEDGMENTS

We thank Dr. Xuejun Sun’s advice for the manuscript.
Damadzic, R., Bigelow, L. B., Krimer, L. S., Goldenson, D. A., Sanders, R. C., Kleinman, J. E., et al. (2001). A quantitative immunohistochemical study of astrocytes in the entorhinal cortex in schizophrenia, bipolar disorder and major depression: absence of significant astrocytosis. *Brain Res. Bull.* 55, 611–618. doi: 10.1016/s0361-9230(01)00529-9

DeMaman, A. S., Homem, J. M., and Lachat, J. J. (2008). Early iron deficiency produces persistent damage to visual tracts in Wistar rats. *Natr. Neurosci.* 11, 283–289. doi: 10.1038/nn1680.0834x219

Deng, Y., Xie, D., Fang, M., Zhu, G., Chen, C., Zeng, H., et al. (2014). Astrocyte-derived proinflammatory cytokines induce hypomyelination in the periventricular white matter in the hypoxic neonatal brain. *PLoS One* 9:e87420. doi: 10.1371/journal.pone.0087420

de Seze, J., and Collongues, N. (2013). Novel advances in the diagnosis and treatment of neuromyelitis optica: is there a need to redefine the gold standard? *Expert Rev. Clin. Immunol.* 9, 979–986. doi: 10.1586/17446661.2013.839944

do Carmo Cunha, J., de Freitas Azevedo Levy, B., de Luca, B. A., de Andrade, M. S., Halassa, M. M., Fellin, T., Takano, H., Dong, J. H., and Haydon, P. G. (2007). Myelination, oligodendrocytes and serious mental illness. *Glia* 62, 1856–1877. doi: 10.1002/glia.22716

Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Dewachter, I., Walter, J., Klockgether, T., et al. (2005). Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP (YF1711) transgenic mice. *J. Neuroinflammation* 2:22. doi: 10.1186/1742-2042-2-22

Hercher, C., Chopra, V., and Beasley, C. L. (2014). Evidence for morphological alterations in prefrontal white matter glia in schizophrenia and bipolar disorder. *J. Psychiatry Neurosci.* 39, 376–385. doi: 10.1503/jpn.130277

Hertz, L., Song, D., Li, B., Du, T., Xu, J., Gu, L., et al. (2014). Signal transduction in astrocytes during chronic or acute treatment with drugs (SSRIs, Antidepressant Drugs, GABA-ergic Drugs and Benzodiazepines) ameliorating mood disorders. *J. Signal Transduct.* 2014:959334. doi: 10.1155/2014/959334

Hesp, Z. C., Goldstein, E. A., Miranda, C. J., Kaspar, B. K., and McTigue, D. M. (2015). Chronic oligodendrogenesis and remyelination after spinal cord injury in mice and rats. *J. Neurosci.* 35, 1274–1290. doi: 10.1523/JNEUROSCI.2568-14.2015

Hindinger, C., Bergmann, C. C., Hinton, D. R., Phares, T. W., Parra, G. L., Hussain, S. et al. (2012). IFN-gamma signaling to astrocytes protects from autoimmune mediated neurological disability. *PLoS One* 7:e42088. doi: 10.1371/journal.pone.0042088

Irace, C., Scorziello, A., Maffettone, C., Pignataro, G., Matrone, C., Adornetto, A., et al. (2005). Divergent modulation of iron regulatory proteins and ferritin biosynthesis by hypoxia/reoxygenation in neurons and glial cells. *J. Neurochem.* 95, 1321–1331. doi: 10.1111/j.1471-4159.2005.03449.x

Ishibashi, T., Dakin, K. A., Stevens, B., Lee, P. R., Kozlov, S. V., Stewart, C. L., et al. (2006). Astrocytes promote myelination in response to electrical impulses. *Neuron* 49, 823–832. doi: 10.1016/j.neuron.2006.02.006

Izawa, T., Yamate, J., Franklin, B. J. R., and Kusumara, M. (2010). Abnormal iron accumulation is involved in the pathogenesis of the demyelinating dmy rat but not in the hypomyelinating mv rat. *Brain Res.* 1349, 105–114. doi: 10.1016/j.brainres.2010.06.030

Ji, Y. F., Zhou, L., Xie, Y. J., Xu, S. M., Zhu, J., Teng, P., et al. (2013). Upregulation of glutamate transporter GLT-1 by mTOR-Akt-NF-small k, CycinIIC cascade in astrocytic oxygen-glucose deprivation. *Glia* 61, 1959–1975. doi: 10.1002/glia.22565

Kang, S. H., Li, Y., Fukaya, M., Lorenzini, L., Cleveland, D. W., Ostrow, L. W., et al. (2013a). Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. *Nat. Neurosci.* 16, 571–579. doi: 10.1038/nn.3557

Kang, Z., Wang, C., Zepf, J., Wu, L., Sun, K., Zhao, J., et al. (2013b). Act1 mediates IL-17-induced EAE pathogenesis selectively in NGf+ glial cells. *Nat. Neurosci.* 16, 1401–1408. doi: 10.1038/nn.3505

Kern, M., Liegl, R. G., Rueping, J., Neubauer, A. S., Haritoglou, C., Lackerbauer, C. A., et al. (2010). Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor and placenta growth factor. *Growth Factors* 28, 211–220. doi: 10.3109/0913799X.2010.536045

Kim, R. Y., Hoffman, A. S., Itoh, N., Ao, Y., Spence, R., Sofroniew, M. V., et al. (2014). Astrocyte CCL2 sustains immune cell infiltration in chronic experimental autoimmune encephalomyelitis. *J. Neuroimmunol.* 274, 53–61. doi: 10.1016/j.jneuroim.2014.06.009

Kimmelberg, H. B., and Nederhaa, M. (2010). Functions of astrocytes and their potential as therapeutic targets. *Neurotherapeutics* 7, 338–353. doi: 10.1016/j.nurt.2010.07.006

Kim, D. B., Su, G., Lenart, B., Ballard, A. J., Meyer, J. W., Ng, L. L., et al. (2004). Increased tolerance to oxygen and glucose deprivation in astrocytes from Na+/H+ exchanger isofrm 1 null mice. *Am. J. Physiol. Cell Physiol.* 287, C12–C21. doi: 10.1152/ajpcell.00560.2003
Kofuji, P., and Newman, E. A. (2004). Potassium buffering in the central nervous system. *Neuroscience* 129, 1045–1056. doi: 10.1016/j.neuroscience.2004.06.008

Kuliewicz-Nawrot, M., Verkhratsky, A., Chvatal, A., Sykova, E., and Rodriguez, J. J. (2012). Astrocytic cytoskeletal atrophy in the medial prefrontal cortex of a triple transgenic mouse model of Alzheimer’s disease. *J. Anat.* 221, 252–262. doi: 10.1111/j.1469-7580.2012.01536.x

Laruelle, M. (2014). Schizophrenia: from dopaminergic to glutamatergic interventions. *Curr. Opin. Pharmacol.* 14, 97–102. doi: 10.1016/j.coph.2014.01.001

Lee, Y., Morrison, B. M., Li, Y., Lengacher, S., Farah, M. H., Hoffman, P. N., et al. (2012). Oligodendroglia metabolically support axons and contribute to neurodegeneration. *Nature* 487, 443–448. doi: 10.1038/nature11314

Lee, W. H., Wang, G. M., Seaman, L. B., and Vannucci, S. J. (1996). Coordinate *GFAP* is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination. *Neuron* 17, 607–615. doi: 10.1016/s0896-6273(00)80194-4

Mats, M., Shen, H. Y., Augusto, E., Wang, Y., Wei, C. J., Wang, Y. T., et al. (2015). Deletion of adenosine A receptors from astrocytes disrupts glutamate homeostasis leading to psychomotor and cognitive impairment: relevance to schizophrenia. *Biol. Psychiatry* 78, 763–774. doi: 10.1016/j.biopsych.2015.02.026

Messerstern, D. J., Murtie, J. C., Le, T. Q., Frost, E. E., and Armstrong, R. C. (2000). Fibroblast growth factor 2 (FGF2) and FGF receptor expression in an experimental demyelinating disease with extensive remyelination. *J. Neurosci.* Res. 62, 241–256. doi: 10.1002/1097-4547(20001015)62:2<241::AID-JNR9>3.0.CO;2-D

Messing, A., Brenner, M., Feany, M. B., Nedergaard, M., and Goldman, J. E. (2012). Alexander disease. *J. Neurosci.* 32, 5017–5023. doi: 10.1523/JNEUROSCI.5384-11.2012

Mills Ko, E., Ma, J. H., Guo, F., Miers, L., Lee, E., Bannerman, P., et al. (2011). How factors secreted from astrocytes impact myelin repair. *J. Neurosci.* 31, 107–120. doi: 10.1523/JNEUROSCI.0304-3901(01)20098-5

Modi, K. K., Sendtner, M., and Pahan, K. (2013). Up-regulation of ciliary factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. *J. Neurochem.* 121, 1073–1086. doi: 10.1111/jn.12126

Morath, D. J., and Mayer-Pröschel, M. (2001). Iron modulates the differentiation of a distinct population of glial precursor cells into oligodendrocytes. *Dev. Biol.* 237, 232–243. doi: 10.1016/j.dbio.2001.03.052

Moreno, C. S., Abdullah, S. L., Brown, A., Arulpragasam, A., and Crocker, S. J. (2014). Deletion of astroglial CXCL10 delays clinical onset but does not affect axonal loss in a murine autoimmune multiple sclerosis model. *J. Neuroinflammation* 11:10. doi: 10.1186/1742-2094-11-10

Morath, D. J., and Mayer-Pröschel, M. (2001). Iron modulates the differentiation of a distinct population of glial precursor cells into oligodendrocytes. *Dev. Biol.* 237, 232–243. doi: 10.1016/j.dbio.2001.03.052

Oh, L. Y., and Yong, V. W. (1996). Astrocytes promote process outgrowth by adult human oligodendrocytes in vitro through interaction between bFGF and astrocyte extracellular matrix. *Glia* 17, 237–253. doi: 10.1002/(SICI)1098-1136(19960717)17:3<241::AID-Glia6>3.0.CO;2-Y

Olabarria, M., Noristani, H. N., Verkhratsky, A., and Rodriguez, J. J. (2011). Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer’s disease mouse model: mechanism for deficient glutamic transmission? *Mol. Neurodegeneration.* 6:55. doi: 10.1186/1750-1073/pnas.91.22.10629

Papadopoulos, M. C., and Verkman, A. S. (2013). Aquaporin water channels in the nervous system. *Nat. Rev. Neurosci.* 14, 265–277. doi: 10.1038/nrn3468

Paul, D., Ge, S., Lemire, Y., Jellison, E. R., Serwanski, D. R., Ruddle, N. H., et al. (2014). Cell-selective knockout and 3D confocal image analysis reveals separate roles for astrocyte-and endothelial-derived CCL2 in neuroinflammation. *J. Neuroinflammation* 11:10. doi: 10.1186/1742-2049-11-10

Pellerin, L., and Magistretti, P. J. (1994). Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. *Proc. Natl. Acad. Sci. U S A* 91, 10625–10629. doi: 10.1073/pnas.91.22.10625

Phillpott, C. C. (2012). Coming into view: eukaryotic iron chaperones and intracellular iron delivery. *J. Biol. Chem.* 287, 13518–13523. doi: 10.1074/jbc.M112.326876

Raasch, J., Zeller, N., van Loo, G., Merkler, D., Mildner, A., Erny, D., et al. (2011). IkappaB kinase beta 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF-kappB in the central nervous system. *Brain* 134, 1184–1198. doi: 10.1093/brain/awq359

Raff, M. C., Miller, R. H., and Noble, M. (1983). A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. *Nature* 303, 390–396. doi: 10.1038/303390a0

Rinneholm, J. E., Hamilton, N. B., Kessaris, N., Richardson, W. D., Bergersen, L. H., and Attwell, D. (2011). Regulation of oligodendrocyte development and myelination by glucose and lactate. *J. Neurosci.* 31, 538–548. doi: 10.1523/JNEUROSCI.3516-10.2011

Roth, A. D., Ramirez, G., Alarcón, R., and Von Bernhardi, R. (2005). Oligodendrocytes damage in Alzheimer’s disease: beta amyloid toxicity and inflammation. *Brain Res.* 38, 381–387. doi: 10.1016/s1079-7364(05)80004-1

Sánchez-Abarca, L. I., Tabernero, A., and Medina, J. M. (2001). Oligodendrocytes damage in Alzheimer’s disease: beta amyloid toxicity and inflammation. *Brain Res.* 38, 381–387. doi: 10.1016/s1079-7364(05)80004-1

Sánchez-Abarca, L. I., Tabernero, A., and Medina, J. M. (2001). Oligodendrocytes damage in Alzheimer’s disease: beta amyloid toxicity and inflammation. *Brain Res.* 38, 381–387. doi: 10.1016/s1079-7364(05)80004-1

Schulz, K., Kroner, A., and David, S. (2012). Iron efflux from astrocytes plays a role in remyelination. *J. Neurosci.* 32, 4841–4847. doi: 10.1523/JNEUROSCI.5328-11.2012
Selvaraju, R., Bernasconi, L., Losberger, C., Graber, P., Kadi, L., Avellan-Adalid, V., et al. (2004). Osteopontin is upregulated during in vivo demyelination and remyelination and enhances myelin formation in vitro. Mol. Cell. Neurosci. 25, 707–721. doi: 10.1016/j.mcn.2003.12.014

Skidmore, F. M., Drago, V., Foster, P., Schmalfuss, I. M., Heilman, K. M., and Streiff, R. R. (2008). Acruloplasminemia with progressive atrophy without brain iron overload: treatment with oral chelation. J. Neurol. Neurosurg. Psychiatry 79, 467–470. doi: 10.1136/jnp.2007.120568

Sofroniew, M. V. (2014). Multiple roles for astrocytes as effectors of cytokines and inflammatory mediators. Neuroscientist 20, 160–172. doi: 10.1177/1073858913504466

Sofroniew, M. V., and Vinters, H. V. (2010). Astrocytes: biology and pathology. Acta Neuropathol. 119, 7–35. doi: 10.1007/s00401-009-0619-8

Sosunov, A. A., Guilfoyle, E., Wu, X., McKhann, G. M. II, and Goldman, J. E. (2013). Phenotypic conversions of “protoplasmic” to “reactive” astrocytes in Alexander disease. J. Neuropath. 33, 7439–7450. doi: 10.1523/JNURSCI.4506-12.2013

Sung, D., Lye-Barthel, M., Masland, R. H., and Jakobs, T. C. (2009). The morphology and spatial arrangement of astrocytes in the optic nerve head of the mouse. J. Comp. Neurol. 516, 1–19. doi: 10.1002/cne.22058

Todorich, B., Pasquini, J. M., Garcia, C. I., Paez, P. M., and Connor, J. R. (2009). Astrocytes from the contused spinal cord inhibit oligodendrocyte precursor numbers in adult CNS and their response following CNS demyelination. Mol. Cell. Neurosci. 25, 252–262. doi: 10.1016/j.mcn.2003.10.014

Tsai, H. H., Frost, E., To, V., Robinson, S., Frenich-Constant, C., Geertman, R., et al. (2002). The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell 110, 373–383. doi: 10.1016/s0092-8674(02)00838-3

Tulpule, K., Robinson, S. R., Bishop, G. M., and Dringen, R. (2010). Uptake of ferrous iron by cultured rat astrocytes. J. Neurosci. Res. 88, 563–571. doi: 10.1002/jnr.22217

van Loo, G., De Lorenzi, R., Schmidt, H., Huth, M., Mildner, A., Schmidt-Supprina, M., et al. (2006). Inhibition of transcription factor NF-κB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat. Immunol. 7, 954–961. doi: 10.1038/ni1372

Viehöver, A., Miller, R. H., Park, S. K., Fischbach, G., and Vartanian, T. (2001). Neuregulin: an oligodendrocyte growth factor absent in active multiple sclerosis lesions. Dev. Neurosci. 23, 377–386. doi: 10.1159/000048721

Wang, Y., Cheng, X., He, Q., Zheng, Y., Kim, D. H., Whittemore, S. R., et al. (2011). Astrocytes from the contused spinal cord inhibit oligodendrocyte differentiation of adult oligodendrocyte precursor cells by increasing the expression of bone morphogenetic proteins. J. Neurosci. 31, 6053–6058. doi: 10.1523/JNURSCI.5524-09.2011

Wang, J., Qiao, J., Zhang, Y., Wang, H., Zhu, S., Zhang, H., et al. (2014). Desvenlafaxine prevents white matter injury and improves the decreased phosphorylation of the rate-limiting enzyme of cholesterol synthesis in a chronic mouse model of depression. J. Neurochem. 131, 229–238. doi: 10.1111/jnc.12792

Wang, W. W., Xie, C. L., Zhou, L. L., and Wang, G. S. (2014). The function of aquaporin4 in ischemic brain edema. Clin. Neurol. Neurosurg. 127, 5–9. doi: 10.1016/j.clineuro.2014.09.012

Williams, M., Pearce, R. K., Hirsch, S. R., Ansorge, O., Thom, M., and Maier, M. (2014). Fibrillary astrocytes are decreased in the subgenual cingulate in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 264, 357–362. doi: 10.1007/s00406-013-0842-8

Woodruff, R. H., Truttiger, M., Richardson, W. D., and Franklin, R. J. (2004). Platelet-derived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelination. Mol. Cell. Neurosci. 22, 9221–9227. doi: 10.1007/s004011-013-0938-3

Zimmermann, N., Zschocke, J., Perisic, T., Yu, S., Holsboer, F., and Rein, T. (2012). TGFB1 induces Jagged1 expression in astrocytes via ALK5 and Smad3 and regulates the balance between oligodendrocyte progenitor proliferation and differentiation. Glia 58, 490–411. doi: 10.1002/glia.20469

Zakin, M. M., Baron, B., and Guillou, F. (2002). Regulation of the tissue-specific expression of transferrin gene. Dev. Neurosci. 24, 222–226. doi: 10.1159/000065690

Zeiger, M., Popken, G., Zhang, J., Xuan, S., Lu, Q. R., Schwab, M. H., et al. (2007). Insulin-like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal in vivo oligodendrocyte development and myelination. Glia 55, 400–411. doi: 10.1002/glia.20469

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Li, Zhang, Chua, Namaka, Deng, Kong and Bi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.